Roche Invests $750m to Double US Manufacturing Plant
Roche is far from alone
Roche’s spending sits within a much wider surge of pharmaceutical reshoring across the United States, a trend accelerated by the threat of tariffs on medicines manufactured overseas under President Donald Trump. Rival drugmakers have announced comparably enormous sums in recent months. Novartis has committed $23bn to building or expanding ten US facilities. Johnson & Johnson has pledged $55bn toward domestic manufacturing, including three entirely new sites, while Eli Lilly is midway through a $27bn investment programme covering four additional plants.
Bristol Myers Squibb has made a similar move, unveiling a $2.3bn “multi-modal manufacturing campus” in Houston, Texas, as part of a broader $40bn, five-year plan covering US research, technology and manufacturing. “This investment reflects our confidence in America’s continued leadership in biopharmaceutical innovation,” said BMS Board Chair and CEO Christopher Boerner. “As part of our $40bn commitment to the United States, we’re building the domestic manufacturing capabilities needed to deliver the next generation of medicines and support future scientific breakthroughs. Houston and the state of Texas offer the talent, infrastructure, and partnership needed to help bring that vision to life.”
